Amylyx Pharmaceuticals Names Trigilio Chief Financial Officer
7 February 2020 - - US-based pharmaceutical company Amylyx Pharmaceuticals, Inc has appointed Jeffrey Trigilio as the company's first chief financial officer, the company said.

In this new role, Jeff will lead the company's financial strategy and business growth and development.

Jeff is as an accomplished financial professional with biotechnology experience from operational as well as investment banking and capital markets roles.

Prior to joining Amylyx, Jeff most recently served as vice president of Finance at BlueRock Therapeutics, an engineered cell therapy company focused on neurology, cardiology and immunology with a lead program in Parkinson's disease.

While there, he oversaw the finance department and served on BlueRock's Leadership Team. Jeff helped develop BlueRock's capital formation plan and enhanced key business processes and systems to facilitate rapid organizational growth.

Previously, Jeff held roles of increasing responsibility at Alexion Pharmaceuticals, a global biotechnology company focused on rare diseases, in corporate strategy and finance, most recently serving as executive director, Strategic Decision Analysis.

At Alexion, he worked closely with executive leadership on long range planning, mergers and acquisitions, manufacturing, pricing and reimbursement and tax planning throughout a significant growth period during which the company expanded into multiple products and therapeutic areas.

Jeff also has experience in investment banking covering healthcare and biopharmaceutical companies at both Credit Suisse and RBC Capital Markets. He holds a B.S. from Cornell University and an MBA from Columbia Business School.

Amylyx Pharmaceuticals is a pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis, Alzheimer's disease and other neurodegenerative diseases.